OCUL
Price
$12.53
Change
+$0.29 (+2.37%)
Updated
Sep 26 closing price
Capitalization
2.18B
43 days until earnings call
RYTM
Price
$99.16
Change
+$0.02 (+0.02%)
Updated
Sep 26 closing price
Capitalization
6.59B
44 days until earnings call
Interact to see
Advertisement

OCUL vs RYTM

Header iconOCUL vs RYTM Comparison
Open Charts OCUL vs RYTMBanner chart's image
Ocular Therapeutix
Price$12.53
Change+$0.29 (+2.37%)
Volume$1.98M
Capitalization2.18B
Rhythm Pharmaceuticals
Price$99.16
Change+$0.02 (+0.02%)
Volume$548.63K
Capitalization6.59B
OCUL vs RYTM Comparison Chart in %
Loading...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RYTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
OCUL vs. RYTM commentary
Sep 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OCUL is a Buy and RYTM is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 29, 2025
Stock price -- (OCUL: $12.53 vs. RYTM: $99.16)
Brand notoriety: OCUL and RYTM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OCUL: 90% vs. RYTM: 91%
Market capitalization -- OCUL: $2.18B vs. RYTM: $6.59B
OCUL [@Biotechnology] is valued at $2.18B. RYTM’s [@Biotechnology] market capitalization is $6.59B. The market cap for tickers in the [@Biotechnology] industry ranges from $98.9B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OCUL’s FA Score shows that 0 FA rating(s) are green whileRYTM’s FA Score has 1 green FA rating(s).

  • OCUL’s FA Score: 0 green, 5 red.
  • RYTM’s FA Score: 1 green, 4 red.
According to our system of comparison, RYTM is a better buy in the long-term than OCUL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OCUL’s TA Score shows that 4 TA indicator(s) are bullish while RYTM’s TA Score has 5 bullish TA indicator(s).

  • OCUL’s TA Score: 4 bullish, 5 bearish.
  • RYTM’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, RYTM is a better buy in the short-term than OCUL.

Price Growth

OCUL (@Biotechnology) experienced а +3.55% price change this week, while RYTM (@Biotechnology) price change was +3.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.00%. For the same industry, the average monthly price growth was +9.18%, and the average quarterly price growth was +54.60%.

Reported Earning Dates

OCUL is expected to report earnings on Nov 10, 2025.

RYTM is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+4.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RYTM($6.59B) has a higher market cap than OCUL($2.18B). RYTM YTD gains are higher at: 77.135 vs. OCUL (46.721). RYTM has higher annual earnings (EBITDA): -159.11M vs. OCUL (-200.5M). OCUL has more cash in the bank: 391M vs. RYTM (291M). RYTM has less debt than OCUL: RYTM (4.19M) vs OCUL (76.9M). RYTM has higher revenues than OCUL: RYTM (156M) vs OCUL (56.7M).
OCULRYTMOCUL / RYTM
Capitalization2.18B6.59B33%
EBITDA-200.5M-159.11M126%
Gain YTD46.72177.13561%
P/E RatioN/AN/A-
Revenue56.7M156M36%
Total Cash391M291M134%
Total Debt76.9M4.19M1,835%
FUNDAMENTALS RATINGS
OCUL vs RYTM: Fundamental Ratings
OCUL
RYTM
OUTLOOK RATING
1..100
9368
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
98
Overvalued
PROFIT vs RISK RATING
1..100
8422
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
4038
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OCUL's Valuation (53) in the Pharmaceuticals Other industry is somewhat better than the same rating for RYTM (98) in the Biotechnology industry. This means that OCUL’s stock grew somewhat faster than RYTM’s over the last 12 months.

RYTM's Profit vs Risk Rating (22) in the Biotechnology industry is somewhat better than the same rating for OCUL (84) in the Pharmaceuticals Other industry. This means that RYTM’s stock grew somewhat faster than OCUL’s over the last 12 months.

OCUL's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as RYTM (100) in the Biotechnology industry. This means that OCUL’s stock grew similarly to RYTM’s over the last 12 months.

RYTM's Price Growth Rating (38) in the Biotechnology industry is in the same range as OCUL (40) in the Pharmaceuticals Other industry. This means that RYTM’s stock grew similarly to OCUL’s over the last 12 months.

RYTM's P/E Growth Rating (100) in the Biotechnology industry is in the same range as OCUL (100) in the Pharmaceuticals Other industry. This means that RYTM’s stock grew similarly to OCUL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
OCULRYTM
RSI
ODDS (%)
Bearish Trend 3 days ago
74%
Bearish Trend 3 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
71%
Bullish Trend 3 days ago
87%
Momentum
ODDS (%)
Bearish Trend 3 days ago
78%
Bullish Trend 3 days ago
84%
MACD
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
88%
Bearish Trend 3 days ago
78%
Advances
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 3 days ago
81%
Declines
ODDS (%)
Bearish Trend 12 days ago
85%
Bearish Trend 5 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
81%
Bullish Trend 3 days ago
88%
Aroon
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RYTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ENHRX10.390.09
+0.87%
Cullen Enhanced Equity Income Retail
VITSX159.281.00
+0.63%
Vanguard Total Stock Market Idx I
TFGRX46.710.27
+0.58%
Touchstone Mid Cap Growth R6
MAGCX31.270.15
+0.48%
BlackRock Advantage Global Institutional
MSHLX58.200.24
+0.41%
Morgan Stanley Inst Growth L

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
+2.37%
EYPT - OCUL
65%
Loosely correlated
+5.38%
IDYA - OCUL
56%
Loosely correlated
+4.44%
NRIX - OCUL
56%
Loosely correlated
+7.20%
IMVT - OCUL
55%
Loosely correlated
+3.57%
CRNX - OCUL
55%
Loosely correlated
+27.92%
More

RYTM and

Correlation & Price change

A.I.dvisor indicates that over the last year, RYTM has been loosely correlated with VRNA. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if RYTM jumps, then VRNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RYTM
1D Price
Change %
RYTM100%
+0.02%
VRNA - RYTM
48%
Loosely correlated
N/A
CRNX - RYTM
44%
Loosely correlated
+27.92%
IDYA - RYTM
41%
Loosely correlated
+4.44%
OCUL - RYTM
41%
Loosely correlated
+2.37%
XENE - RYTM
41%
Loosely correlated
+4.00%
More